Carelon Medical Benefits Management Updates Clinical Appropriateness Guidelines
Effective Nov. 15, 2026, Carelon Medical Benefits Management Inc., a partner of Anthem Blue Cross, will apply updates relevant to genetic testing,...
Effective Nov. 15, 2026, Carelon Medical Benefits Management Inc., a partner of Anthem Blue Cross, will apply updates relevant to genetic testing, somatic tumor testing, and testing for hematologic malignancies in its Clinical Appropriateness Guidelines.
For genetic testing, the updates require all components of a test to demonstrate clinical utility. Criteria were added for genetic liquid biopsy indicating that RNA fusion, expression, and whole transcriptome analysis using ctRNA are not medically necessary. The stages of breast cancer when molecular profile testing is indicated were also expanded to include recurrent and locally advanced stages. For individuals without malignancy for whom liquid biopsy is used for screening,the guidelines now include additional test examples, including CancerGuard.
A new general requirement for solid tumors stipulates that all components of a test must demonstrate clinical utility. Targeted RNA-based fusion analysis is now allowed using next-generation sequencing if noted in cancer-specific criteria.
For patients with advanced solid tumors seeking tissue agnostic testing, HER2 testing will now be allowed, and a criterion for FGFR1/2/3 fusions or pathogenic/likely pathogenic variants has been removed. Several changes have also been made for specific cancer types and hematologic malignancies. A complete list of all laboratory-specific updates is available on the Anthem website.
Effective Nov. 15, 2026, Carelon Medical Benefits Management Inc., a partner of Anthem Blue Cross, will apply updates relevant to genetic testing,...
Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.
Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).